Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
An anti-BCMA CAR-T therapy appeared to be safe and effective for patients with relapsed or refractory multiple myeloma.
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
A new study gives a comprehensive picture of patient quality of life before and after salvage transplant.
Interestingly, a number of patients ultimately achieving a sustained complete response initially experienced a partial response to this CAR T-cell therapy.
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.
Researchers evaluated 15 studies in patients with myelodysplastic syndrome to determine the prognostic value of mutations in the SF3B1 gene.
Researchers found that permethrin application was associated with changes in hematologic parameters that persisted for a least 3 weeks.
Subgroup analyses of outcomes following development of disease refractory to a CD38-targeting agent suggested that carfilzomib + an alkylator have some efficacy.
Twice-weekly administration of carfilzomib requires patients to receive carfilzomib infusions on 2 consecutive days each week.
The efficacy and safety of autologous hematopoietic stem cell transplantation (auto-HCT) performed during the era of novel agents was comparable between elderly and younger patients with multiple myeloma, according to results of a retrospective study published in Bone Marrow Transplantation. Uncertainty remains regarding the risks and benefits of auto-HCT in elderly patients (≥ 65 years).…
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Takeda will work with Memorial Sloan Kettering Cancer Center to develop CAR-T therapies for multiple myeloma.
Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.
Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.